Skip to main content
Equibles

AUROPHARMA · Aurobindo Pharma Limited · Financials

Use AUROPHARMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AUROPHARMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,829.00 INR +24.00 (+1.33%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 221.71K Avg daily vol (14 sessions) 123K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
336.53B +6.1%
FY2026 Revenue FY2018–FY2026
Net Income
35.05B +0.5%
FY2026 Net Income FY2018–FY2026
Operating Cash Flow
55.26B +40.8%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2018
INR 369.13B 336.53B 317.24B 290.02B 248.55B 234.55B 247.75B 230.99B 165B
INR 19.61B 17.78B 16.49B 15.22B 12.45B 11.27B 10.55B 9.67B 5.58B
INR 3.95B 3.84B 4.57B 2.9B 1.4B 486.4M 744.9M 1.6B 777.1M
INR 18.45B 16.09B 15.83B 12.11B 6.85B 7.26B 20.1B 9.14B 8.18B
INR 39.9B 35.05B 34.86B 31.73B 19.28B 26.48B 53.39B 28.31B 0
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 11.99B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.